Close Menu

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray today initiated coverage of cancer diagnostics firm OncoCyte with an Overweight rating and a $6 target on the company's stock.

In a research note, analyst William Quirk said that in his view OncoCyte's test, called DetermaVu, is potentially best in class for lung cancer diagnosis, and he believes the US Centers for Medicare & Medicaid Services could start reimbursing for the test as early as late 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.